Sildenafil citrate

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pre-eclampsia

Conditions

Pre-eclampsia

Trial Timeline

Sep 1, 2004 → Apr 1, 2006

NCT ID

NCT00141310

About Sildenafil citrate

Sildenafil citrate is a phase 2 stage product being developed by Pfizer for Pre-eclampsia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00141310. Target conditions include Pre-eclampsia.

What happened to similar drugs?

0 of 1 similar drugs in Pre-eclampsia were approved

Approved (0) Terminated (0) Active (1)

🔄FurosemidePacific BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00878943	Pre-clinical	Completed	—	—	Pulmonary Arterial Hypertension
NCT03356353	Phase 3	UNKNOWN	Mar 12, 2018	Jan 1, 2022	End Stage Heart Failure
NCT01365585	Pre-clinical	Completed	Jul 1, 2011	Oct 1, 2011	Pulmonary Arterial Hypertension
NCT00772135	Pre-clinical	UNKNOWN	Sep 1, 2008	Apr 1, 2009	Congenital Heart Disease
NCT00517933	Phase 3	Completed	Aug 1, 2007	Oct 1, 2009	Pulmonary Fibrosis
NCT00468650	Approved	Completed	Jun 1, 2007	Feb 1, 2008	Erectile Dysfunction
NCT00245258	Approved	Completed	Nov 1, 2005	Sep 1, 2006	Impotence
NCT00159900	Approved	Completed	May 1, 2005	Jan 1, 2006	Erectile Dysfunction
NCT00150358	Approved	Completed	Mar 1, 2005	Nov 1, 2005	Impotence
NCT00151463	Approved	Completed	Jan 1, 2005	—	Impotence
NCT00141310	Phase 2	Terminated	Sep 1, 2004	Apr 1, 2006	Pre-eclampsia
NCT00317421	Phase 2	Completed	Mar 1, 2004	Nov 1, 2005	Hypertension
NCT00159861	Phase 3	Completed	Jul 1, 2003	Jan 1, 2006	Pulmonary Hypertension
NCT00159887	Phase 3	Completed	Dec 1, 2002	Feb 1, 2007	Pulmonary Hypertension

Competing Products

3 competing products in Pre-eclampsia

See all competitors

Product	Company	Stage	Hype Score
Placebo + RLX030	Novartis	Phase 2	27
recombinant human relaxin	Novartis	Phase 1	33
Furosemide	Pacific Biosciences	Phase 3	30